Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Shares Outstanding (Weighted Average)
Others
Ratios

Immuneering (IMRX) Cost of Revenue: 2020-2022

Historic Cost of Revenue for Immuneering (IMRX) over the last 3 years, with Sep 2022 value amounting to $19,343.

  • Immuneering's Cost of Revenue fell 91.17% to $19,343 in Q3 2022 from the same period last year, while for Sep 2022 it was $364,343, marking a year-over-year decrease of 74.34%. This contributed to the annual value of $158,122 for FY2022, which is 86.29% down from last year.
  • Immuneering's Cost of Revenue amounted to $19,343 in Q3 2022, which was down 59.65% from $47,933 recorded in Q2 2022.
  • Over the past 5 years, Immuneering's Cost of Revenue peaked at $473,233 during Q4 2020, and registered a low of $19,343 during Q3 2022.
  • For the 3-year period, Immuneering's Cost of Revenue averaged around $235,446, with its median value being $237,058 (2020).
  • In the last 5 years, Immuneering's Cost of Revenue rose by 24.93% in 2021 and then tumbled by 91.17% in 2022.
  • Over the past 3 years, Immuneering's Cost of Revenue (Quarterly) stood at $473,233 in 2020, then plummeted by 56.42% to $206,221 in 2021, then crashed by 91.17% to $19,343 in 2022.
  • Its Cost of Revenue stands at $19,343 for Q3 2022, versus $47,933 for Q2 2022 and $90,846 for Q1 2022.